source
- Chiesi to buy KalVista in $1.9B deal for rare disease drugThe acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.BioPharma Dive · 3mo ago↗ source
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…BioPharma Dive · 3mo ago↗ source
- Pfizer deals extend patent life for a top-selling rare disease drugSettlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.